Henry Schein (NASDAQ:HSIC – Get Free Report) issued an update on its FY 2026 earnings guidance on Monday. The company provided earnings per share guidance of 5.420-5.480 for the period, compared to the consensus estimate of 5.540. The company issued revenue guidance of $13.8 billion-$13.9 billion, compared to the consensus revenue estimate of $13.8 billion.
Wall Street Analysts Forecast Growth
HSIC has been the topic of a number of analyst reports. Leerink Partners set a $92.00 price target on shares of Henry Schein and gave the stock a “market perform” rating in a research note on Wednesday, October 14th. Stifel Nicolaus set a $95.00 price objective on Henry Schein in a research note on Wednesday, August 5th. Piper Sandler lifted their price target on shares of Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Weiss Ratings raised Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, August 21st. Finally, Barrington Research set a $104.00 target price on shares of Henry Schein in a research note on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.57.
Read Our Latest Stock Analysis on HSIC
Henry Schein Price Performance
Shares of NASDAQ HSIC opened at $86.22 on Monday. The stock has a market capitalization of $9.53 billion, a price-to-earnings ratio of 23.62, a P/E/G ratio of 1.51 and a beta of 0.87. Henry Schein has a 12-month low of $68.70 and a 12-month high of $92.18. The firm’s 50-day moving average price is $85.91 and its 200-day moving average price is $81.54. The company has a current ratio of 1.33, a quick ratio of 0.76 and a debt-to-equity ratio of 0.62.
Henry Schein (NASDAQ:HSIC – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.20. The company had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.48 billion. Henry Schein had a return on equity of 16.39% and a net margin of 3.07%. Henry Schein’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 EPS. On average, equities research analysts anticipate that Henry Schein will post 5.55 EPS for the current fiscal year.
Henry Schein Company Profile
Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.
Read More
- Five stocks we like better than Henry Schein
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
